Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability

@article{Chez2007MemantineAA,
  title={Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability},
  author={Michael G. Chez and Quinn Burton and Timothy Dowling and Min-Te Chang and Pavan Khanna and C. Kramer},
  journal={Journal of Child Neurology},
  year={2007},
  volume={22},
  pages={574 - 579}
}
Autism and Pervasive Developmental Disorder Not Otherwise Specified are common developmental problems often seen by child neurologists. There are currently no cures for these lifelong and socially impairing conditions that affect core domains of human behavior such as language, social interaction, and social awareness. The etiology may be multifactorial and may include autoimmune, genetic, neuroanatomic, and possibly excessive glutaminergic mechanisms. Because memantine is a moderate affinity… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this research study is to learn if the medication Memantine Hydrochloride (the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto… Expand
ConditionsDown Syndrome, Intellectual Disability
InterventionDrug
Use of Memantine in Autism Spectrum Disorder: a Case Report
TLDR
Memantine appeared effective for treating core deficits in verbal and non-verbal communication in a child with autism, and improvement in communication was noted over the course of one year of treatment with memantine. Expand
Pharmacologic Treatment of Behavioral Symptoms Associated With Autism and Other Pervasive Developmental Disorders
TLDR
Serotonin reuptake inhibitors are of limited efficacy in children and adolescents, but risperidone and aripiprazole have been shown to reduce these symptoms, and there remains a need for further safety and efficacy research in this area. Expand
Drug therapy in autism: a present and future perspective.
TLDR
The recent approaches to autism treatment included various non-pharmacological and pharmacological therapy such as food supplementation, detoxification, treatment of neuro inflammation, immunologic treatments and psychotropic medications, which are found to be effective in treating various behavioral symptoms of autism. Expand
Pharmacotherapy to control behavioral symptoms in children with autism
TLDR
Psychotropic medications examined in this review include serotonin reuptake inhibitors, typical and atypical antipsychotics, medications used to treat attention-deficit/hyperactivity disorder, naltrexone, buspirone, divalproex sodium, lamotrigine, levetiracetam, memantine, mirtazapine, riluzole, pioglitazone, and topiramate. Expand
Efficacy of Memantine as Adjunct Therapy for Autism Spectrum Disorder in Children Aged <14 Years
TLDR
Memantine administration as adjunct therapy can be more effective in improvement of ASD symptoms in children than ABA alone and can be considered as a new selective adjunct therapy. Expand
Psychopharmacological Interventions in Autism Spectrum Disorder
TLDR
The physician should be better able to prescribe the appropriate psychotropic medication to treat symptoms of ASD and identify the side effects of the psychotropic medications used to treat ASD. Expand
A retrospective analysis of memantine use in a pediatric neurology clinic
TLDR
Memantine is generally well-tolerated in children, and may have potential benefit for a broad range of pediatric neurodevelopmental disorders. Expand
Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial
TLDR
This proof-of-concept clinical study will allow pilot-testing of memantine for both clinical effectiveness and tolerability/safety and will provide clinically relevant solid information on potential new mechanisms and medication treatment in obsessive-compulsive and autism spectrum disorders. Expand
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
TLDR
The diversity of numerous aetiological factors and the alterations in variety of neurotransmitter generation, release and function linked to ASD are discussed with focus on drugs currently used to manage neuropsychiatric symptoms related to ASD. Expand
Immune therapy in autism: Historical experience and future directions with immunomodulatory therapy
TLDR
Prenatal, genetic, and observed immune aspects of the autism condition that may be risk factors in the presentation of the autistic clinical phenotype are reviewed and new theories that may lead to the development of disease modification or preventative therapeutic options in the near future are offered. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder.
  • A. Hardan, B. Handen
  • Psychology, Medicine
  • Journal of child and adolescent psychopharmacology
  • 2002
TLDR
Double-blind, placebo-controlled investigations are needed to provide further evidence of the potential benefits of donepezil to patients with autistic disorder. Expand
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
TLDR
Improvements in both expressive speech and overall autistic behavior showed gains were statistically significant and supported the hypothesis that treatment with cholinergic enhancing drugs in autistic spectrum disorders yields positive therapeutic effects. Expand
Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.
  • B. King, D. M. Wright, +20 authors E. Cook
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2001
TLDR
Improvements in behavioral ratings following treatment with amantadine suggest that further studies with this or other drugs acting on the glutamatergic system are warranted, and the design of these drug trials in children with autistic disorder must take into account the possibility of a large placebo response. Expand
Neuroglial activation and neuroinflammation in the brain of patients with autism
TLDR
It is indicated that innate neuroimmune reactions play a pathogenic role in an undefined proportion of autistic patients, suggesting that future therapies might involve modifying neuroglial responses in the brain. Expand
Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005
TLDR
A retrospective review of 24-hour ambulatory digital EEG data collected from 889 ASD patients presenting between 1996 and 2005 shows that 540 of 889 subjects had abnormal EEG epileptiform activity in sleep with no difference based on clinical regression. Expand
Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years--United States, 2003-2004.
TLDR
Estimates suggest that, as of 2003-2004, autism had been diagnosed in at least 300,000 U.S. children aged 4-17 years and were associated with reported social, emotional, and behavioral symptoms and specialized needs. Expand
Outcome Measures for Clinical Drug Trials in Autism
TLDR
This paper identifies instruments and measures that may be appropriate for randomized clinical trials in participants with autism spectrum disorders (ASDs), and recommends routine elicitation of side effects, height and weight, vital signs, and extrapyramidal side-effects assessment. Expand
The Neurobiology of Autism
TLDR
Thoroughly updated, The Neurobiology of Autism remains the best single-volume work on the wide array of research being conducted into the causes, characteristics, and treatment of autism. Expand
A pilot study of D-cycloserine in subjects with autistic disorder.
TLDR
D-cycloserine treatment resulted in significant improvement in social withdrawal in subjects with autism, and d-Cycloserine was well tolerated at most of the doses used in this study. Expand
Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data
TLDR
Preclinical data on memantine is summarized to provide evidence that it is indeed possible to develop clinically well tolerated NMDA receptor antagonists, a fact reflected in the recent interest of several pharmaceutical companies in developing compounds with similar properties to memantine. Expand
...
1
2
3
...